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Abstract
Statins have the potential to reduce breast cancer incidence and recurrence as shown in both 
epidemiologic and laboratory studies. The purpose of this study was to evaluate the effect of a 
lipophilic statin, atorvastatin, on breast cancer biomarkers of risk [mammographic density (MD) 
and insulin growth factor 1 (IGF-1)] in high-risk premenopausal women.
Premenopausal women at increased risk for breast cancer received either 40 mg of atorvastatin or 
placebo for 1 year. Biomarker assessment was performed prior to initiation and at completion of 
study medication. MD was determined using both Breast Imaging Reporting and Data System and 
the visual analogue scale. Serum IGF-1 was determined by ELISA assay at the end of the study.
Sixty-three women were enrolled between December 2005 and May 2010. Sixteen (25%) women 
withdrew. The mean age of participants was 43 (range, 35–50), 100% were white, and the average 
body mass index (BMI) was 26.4. The statin group demonstrated a significant decrease in 
cholesterol and low-density lipoprotein (LDL), suggesting compliance with study medication. 
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After accounting for BMI, there was no difference in change in MD between groups. There was a 
significant increase in serum IGF-1 in the statin group.
In this multi-institutional randomized prospective clinical trial of premenopausal women at 
increased risk for breast cancer, we did not see an effect of atorvastatin on MD. Further 
investigation of statins may be warranted; however, design of prior trials and potential mechanism 
of action of the agent need to be considered in the design of future trials.
 Introduction
There are several chemoprevention options for breast cancer prevention; however, these 
agents [selective estrogen response modifiers (SERMs) and aromatase inhibitors] only 
prevent estrogen receptor–positive (ER+) breast cancer (1, 2). In addition, toxicity and 
tolerability are significant barriers to utilization of these agents (3, 4). Agents which prevent 
ER− breast cancer with improved tolerability are needed.
Statins are well tolerated and may prevent both ER+ and ER− breast cancer (5–7). There are 
strong biologic data supporting a preventive effect (8–10). Epidemiologic studies have 
generally demonstrated a favorable effect of statins on breast cancer (7, 11–13); however, 
other studies have not shown this same effect (10, 14, 15). Meta-analyses of both 
observational studies and randomized controlled trials have not shown benefit of statins in 
breast cancer (16–21), although many of the authors and others suggest that short follow-up 
and inclusion of both lipophilic and hydrophilic statins may account for the lack of breast 
cancer prevention effect (22, 23).
Several short-term single-arm intervention studies evaluating statin effects on breast cancer 
biomarkers have been performed also with mixed results (24–26). The authors suggest that 
sample size, drug dose, and/or duration may have contributed to negative results (24, 25). 
We sought to evaluate the effect of statins for longer duration in a randomized placebo-
controlled trial of high-risk, premenopausal women.
Among the available biomarkers for breast cancer risk, mammographic density (MD) is the 
most widely accepted (27, 28). MD is associated with a 4- to 6-fold increased risk of breast 
cancer for women with highest MD (defined as extremely dense or >75% dense; ref. 29). In 
addition, MD is modifiable (30–33), and modification is associated with change in risk (34, 
35). Serum insulin growth factor-1 (IGF-1) is another important breast cancer biomarker 
(36–39). IGF-1 levels have been associated with risk, especially for premenopausal women 
(40–45). There is evidence to suggest that inhibition of mevalonate (by statins and other 
compounds) may affect both expression of IGF and levels of free IGF-1 (46). Given the 
acceptance of MD as an intermediate biomarker, and the association of MD and risk, this 
was chosen as our primary endpoint. IGF-1 levels were chosen as a secondary endpoint 
given the association of IGF-1 and premenopausal breast cancer and effect of statins on IGF 
levels (40–46). Importantly, both of these biomarkers have been used in prior biomarker 
studies involving statins and other potential breast cancer prevention agents (24, 25, 47). 
Given the cost and resources involved in large-scale randomized trials of chemoprevention 
agents, we sought to gather more definitive data supporting a chemopreventive effect of 
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statins through a longer exposure (1 year) in a placebo-controlled trial of high-risk 
premenopausal women examining biomarker endpoints.
 Materials and Methods
This was a multi-institutional, randomized, placebo-controlled trial examining the effect of 1 
year of atorvastatin (40 mg), or placebo on both MD and serum IGF-1 in high-risk 
premenopausal women. This study was conducted at several institutions, including the 
University of Vermont, Dana Farber Cancer Institute, Southern Nevada Cancer Research 
Foundation, Southeastern Medical Oncology Center, and Delaware Christiana Care. The 
study was approved by the Institutional Review Board at each of the sites.
Women were eligible if age was 35 to 55 years, they were premenopausal (defined as having 
at least 4 menstrual cycles in 6 months, or a serum estradiol level in the premenopausal 
range for women with a hysterectomy) and at high risk for breast cancer (defined as meeting 
one of the criteria outlined in Fig. 1). Women were excluded if they had taken statins in the 
prior 6 months, were taking hormonal replacement therapy or a SERM or taking drugs that 
increase the risk of statin-induced myopathy or rhabdomyolysis (i.e., niacin, protease 
inhibitors, verapamil, gemfibrozil, cyclosporine, clofibrate/fenofibrate, or any CYP3A4 
inhibitor). Women who were pregnant, planning to become pregnant, were breastfeeding, 
had underlying liver disease, or had known hypersensitivity to atorvastatin were excluded.
After signing written informed consent and completing an on-study evaluation [including 
physical examination, body mass index (BMI), system review, and questionnaires], women 
were randomized to receive either daily placebo or 40 mg of atorvastatin. Women were 
monitored for sensitivity to statins [liver enzymes, creatine phosphokinase (CPK), and 
muscle injury] at 6 weeks, 3, 6, and 9 months. Study participants completed questionnaires 
regarding medical history, diet, and physical activity at baseline (on-study) and 12 months. 
Lipid profiles were determined at baseline and 12 months.
 Serum IGF-1
Blood was collected at baseline and 1 year for measurement of serum IGF-1. Serum IGF-1 
concentrations were analyzed by a sandwich ELISA (human IGF-1 Quantikine 
Immunoassay; R&D Systems) after acid extraction of samples to remove endogenous 
binding proteins. Standards were recombinant human IGF-1. All samples were analyzed in a 
single run with an intra-assay coefficients of variation (CV) for rhIGF-1 of 9.2% and a 
sensitivity of 29 pg/mL. The investigator measuring IGF-1 was blinded to patient 
characteristics and treatment.
 Mammographic density
Mammograms were obtained at baseline and 12 months. MD was determined using the 
Breast Imaging Reporting and Data System (BIRADs) category from the clinical report (48) 
in which BIRADs 1 correlates with an almost entirely fatty breast (<25% glandular); 
BIRADs 2 shows scattered fibroglandular densities (25%–50% glandular); BIRADs 3 shows 
the breast tissue is heterogeneously dense (51%–75% glandular); and BIRADS 4 shows the 
breast tissue is extremely dense (>75% glandular). MD was also determined using the visual 
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analogue scale (VAS; ref. 49) by M. Wood and B. Sussman. VAS density scoring was 
performed twice for a single view of each mammogram, and a median score was calculated. 
Investigators determining MD were blinded to patient characteristics and treatment.
 Statistical considerations
Based on the review of literature related to change in MD for women taking either hormone 
replacement therapy (HRT) or Tamoxifen, a decrease of 7.9% (33) would be considered 
clinically significant, and the control group would be expected to change 3.5%. This study 
was therefore designed to enroll 100 women, which would give an 80% power to detect a 
3.5% difference in density (at the alpha = 0.05 level).
Descriptive statistical methods were used to show the distribution of study participant 
characteristics at baseline. Means and SDs were calculated to summarize continuous 
variables, whereas frequencies and percentages were determined to summarize categorical 
variables. Univariate inferential techniques, t tests, and χ2 tests were used to compare 
baseline characteristics for the placebo and atorvastatin groups.
To examine the change in outcomes over time, 95% confidence intervals were constructed to 
estimate the change in total cholesterol, high-density lipoprotein (HDL), LDL, IGF-1, and 
VAS for both the atorvastatin and placebo groups. Dependent t tests were used to identify 
statistically significant differences over time. Independent t tests were used to compare 
changes in these measures between groups. χ2 methods were used to examine changes in 
BIRADs categories between the two study groups over time. Regression methods were used 
to examine the effect of BMI on outcome measures.
 Results
Sixty-three women were enrolled between December 2005 and May 2010. Sixteen women 
(25%) withdrew from the study; six due to laboratory abnormalities, four due to side effects, 
and four were lost to follow-up (see Fig. 2 for further detail). The dropout rate over time 
(Fig. 3) reveals a dropout rate at 6 months of 17%. Forty-seven women (74%) completed 1 
year of study drug and were included in the outcome analysis. Patient characteristics are 
shown in Table 1. Women ranged in age from 35 to 50 years, 100% were Caucasian, average 
BMI was 26, and 66% of women entered had a strong family history of breast cancer. The 
two groups (placebo and atorvastatin) were well balanced, with no statistically significant 
differences in baseline characteristics (Table 1).
 Toxicity
Little toxicity was reported by women in this study. Elevated CPK was seen in four 
participants (two on placebo). Elevations in liver enzymes were seen in three individuals 
(one on placebo).
 Lipid profiles
Paired baseline and posttreatment fasting lipid profiles were available for 89% (n = 42) of 
the study participants. The average total cholesterol in the placebo group was 184.5 mg/dl at 
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baseline and was unchanged (186.3 mg/dl, P > 0.05) after 1 year. By contrast, cholesterol 
levels in the atorvastatin group were 196.0 mg/dl at baseline and were significantly reduced 
after 1 year (152.4 mg/dl; P < 0.05).
Results for HDL and LDL levels over time were available for 57% (n = 13) of the 
atorvastatin group and 67% (n = 16) of the placebo group. In the atorvastatin group, there 
was a significant decrease in LDL over time (P < 0.001) but no change in HDL. Results are 
summarized in Table 2.
 Mammographic density
MD was measured at baseline and after 1 year using both the BIRADs and VAS methods. 
BIRADs measures were available for 94% of study participants (n = 44), and VAS 
calculations were determined for 85% (n = 40). Although not statistically significant, a 
greater proportion of women in the placebo group had increased MD (BIRADs 3 or 4) 
compared with the atorvastatin group at baseline (84% and 61%, respectively). The BIRADs 
measure of MD in the majority of women in both groups did not change after 1 year (Table 
3). Moreover, the changes in BIRADs category over time were not significant (P = 0.244; 
Table 3).
The mean MD at baseline using the VAS method was similar for both groups (33.7% for 
placebo vs. 31.4% for the atorvastatin group). There was no significant change in VAS 
density in either group over time (Table 3). This was true whether change was examined for 
the group as a whole or when determining change for each participant.
 Serum IGF-1 analysis
Paired samples for baseline and 1-year IGF-1 levels were available for 87% (n = 41) of study 
participants. Mean values for both groups at baseline were similar (87.8 ng/mL for the 
placebo and 85.0 ng/mL for the atorvastatin group, P = 0.71). At 12months, the placebo 
group had an average decrease of 3.3 ng/mL (not significant), whereas the atorvastatin group 
had an average increase of 14.7 ng/mL (P = 0.021). The difference in change was 
significantly different between the two groups (P = 0.031; Table 4).
 Discussion
In this multicenter, randomized, placebo-controlled trial involving high-risk premenopausal 
women, we were unable to demonstrate an effect of the lipophilic statin, atorvastatin, on MD 
(the primary endpoint of the study). We did demonstrate a decrease in cholesterol 
(suggesting a high degree of compliance) and observed an increase in IGF-1 with 
atorvastatin.
Our findings are somewhat similar to other short-term biomarker studies of statins for breast 
cancer prevention. Higgins and colleagues evaluated the effects of 24 to 28 weeks of 
simvastatin on the contralateral breast in 45 women (ranging in age from 38–74) with stage 
0 to III breast cancer (25). They observed a decrease in cholesterol but no change in MD. 
They did find a decrease in CRP and estrone sulfate. IGF-1 was not evaluated. Vinayak and 
colleagues evaluated 6 months of lovastatin in 26 high-risk women ranging in age from 25 to 
Ji et al. Page 5
Cancer Prev Res (Phila). Author manuscript; available in PMC 2016 July 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
62 (24). They saw no change in cholesterol profiles or biomarkers (cytologic atypia, MD, 
IGF levels, or CRP). Compared with these studies, our study was larger, treated women for a 
longer time, and was placebo controlled.
Our study was originally designed to enroll 100 women, giving an 80% power to detect a 
3.5% difference in density (at alpha = 0.05). We were forced to stop the study early due to 
lack of funding. This study should therefore be considered underpowered, with an increased 
likelihood of a Type I error. In addition, interpretation of MD is known to be subjective with 
high intra-and inter-reader variability (50, 51). The methods we used may have been too 
imprecise to see a significant change in MD. The BIRADs categories each span 25 
percentage points, so a change of less than 25% might not have been detected if the category 
did not change. In addition, MD done by the VAS method led to clustering of measurements 
around whole numbers, potentially missing smaller differences.
Given that our and other studies have failed to demonstrate a change in MD while 
identifying significant change in other biomarkers, it is important to consider that statins 
may not act via change in MD. Other studies of agents known to prevent breast cancer, such 
as aromatase inhibitors, have not identified change in MD (47). Statins have however, been 
shown to modulate other biomarkers. Garwood and colleagues demonstrated reduced 
proliferation and increased apoptosis as indicated by changes in Ki-67 and cleaved 
caspase-3, respectively, in women with stage 0 to 1 breast cancer treated with 3 to 6 weeks 
of fluvastatin (26). Higgins and colleagues identified a significant change in hsCRP and 
estrone sulfate levels after 6 months of simvastatin (25).
Our observation of increased IGF-1 after 1 year of atorvastatin was unexpected. Given the 
randomized design of this study and that the two groups were well balanced, this is likely a 
real effect. We are, however, at a loss to explain the mechanism of this effect. Circulating 
IGF-1 is affected by numerous variables, including age, sex, exercise, stress level, and 
circadian rhythm. Recent studies show that IGF-1 levels are associated with HDL levels, and 
are inversely associated with total cholesterol and LDL (52, 53). We did not find this same 
association, but our sample size may have been too small to see this effect.
Despite our findings, there is a strong biologic rationale for statins as a preventive therapy. 
Statins decrease both mevalonate and its downstream lipid products which interfere with the 
function of RAS and other G proteins leading to decreased proliferation and survival (54). 
Statins are also known to cause cell-cycle arrest by affecting the G1 to S transition, partially 
due to increased CDK (p21/p27) activity (55–57). Campbell reported that statin use 
suppressed the MAPK pathway and increased the expression of p21. Such effects were more 
pronounced in ER− cell lines (9). Induction of apoptosis by statins may be another 
mechanism of cancer prevention (58). One recent study indicated such an inhibitory effect 
may work through upregulated PTEN expression (59). The effects of statins on proliferation 
and apoptosis provide a strong biologic rationale for a preventive effect (60).
This study has several strengths: it is multi-institutional and placebo controlled, women were 
treated for 1 year (longer than other studies), and our cohort was not only high risk but 
premenopausal. In addition, there was a high degree of compliance, demonstrated by 
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lowered lipid levels over time. There are, however, limitations that must be considered 
including the small sample size and high dropout rate. Our dropout rate is higher than other 
studies of statins and biomarkers (24, 25). However, the dropout rate at 6 months of 17% is 
similar to the prior two studies of 6-month duration (10% and 13%; refs. 24, 25).
In conclusion, the strong biologic rationale and observational studies supporting the effect of 
statins as prevention therapy for ER− and ER+ breast cancer suggest that additional 
investigation of statins may be warranted. Design of these trials might focus on biomarkers 
that have shown effects of statins, such as proliferation, apoptosis, and inflammation. 
However, these biomarkers are not as strongly linked to breast cancer development as MD. 
In addition, more precise measurement of MD (such as fully automated methods) may reveal 
a significant change.
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Figure 1. 
Definition of high risk (61).
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Figure 2. 
Trial design.
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Figure 3. 
Patient withdrawals over time.
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Table 1
Baseline characteristics
Characteristic
Placebo
(n = 24)
Mean (SD)
or n (%)
Atorvastatin
(n = 23)
Mean (SD)
or n (%) P value
Age 43 (4.5) 43.7 (4.1) 0.6772
BMI 25.8 (4.5) 27.0 (6.8) 0.5108
Race, white 22 (100%) 23 (100%) >0.999
Eligibility risk criteria
  Strong family history 14 (63%) 16 (70%)
  History of ADH/LCIS 6 6
  BRCA mutation carrier 1 0
  History of BC/DCIS 1 0
  Gail risk alone 0 1
Calculated Gail risk (61)
  5-year risk 2.3 (1.8) 2.9 (2.0) 0.3430
  Lifetime risk 23.9 (8.6) 28.2 (11.4) 0.1834
Total cholesterol mg/dl 184.5 (28.6) 196.0 (34.5) 0.2224
HDL mg/dl 63.2 (17.1) 62.2 (12.0) 0.8269
LDL mg/dl 102.3 (26.8) 114.1 (35.6) 0.2036
IGF ng/mL 87.8 (27.7) 85.0 (22.4) 0.7171
Density measurements
  VAS percent density 33.7 (18.5) 31.4 (24.8) 0.7311
  BIRAD density category
    1 2 (8%) 1 (4%)
    2 1 (4%) 8 (35%) 0.060
    3 16 (67%) 12 (52%)
    4 4 (17%) 2 (9%)
Abbreviations: ADH, atypical ductal hyperplasia; BC, breast cancer; DCIS, ductal carcinoma in situ; LCIS, lobular carcinoma in situ.
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Table 3
Change in MD, baseline to 12-month follow-up
Placebo (n = 21) Atorvastatin (n = 23)
BIRAD category N (%) N (%) P value
No change 14 (58%) 16 (70%)
Increase 1 (4%) 3 (13%) 0.244
Decrease 6 (25%) 4 (17%)
Placebo (n = 20) Atorvastatin (n = 20)
VAS Mean change (95% CI) Mean change (95% CI)
−0.3 (−3.8–3.2) 0 (−3.9–3.9) 0.9056
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Table 4
Change in IGF-1, baseline to 12-month follow-up
Placebo (n = 21) Atorvastatin (n = 20)
Mean change (95% CI) Mean change (95% CI) P value
IGF-1 (ng/mL) −3.3 (−14.7–8.2) 14.7 (2.4–27.0) 0.0308
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